ArticleThoracic cancer2022
PRKCB is relevant to prognosis of lung adenocarcinoma through methylation and immune infiltration.
Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Adenylate cyclase 4 suppresses malignant progression of lung adenocarcinoma through interaction with protein kinase C beta.Translational cancer research · 2026Article
- Identification and preliminary examination of prognostic genes linked to calcium metabolism in colorectal cancer.Journal of gastrointestinal oncology · 2026Article
- Correlating obstructive sleep apnea and lung adenocarcinoma using hub gene signatures and molecular mechanisms.Discover oncology · 2026Article
- Exploring the biological functions of PCOS: identifying hub androgen-related genes through bioinformatics.Frontiers in medicine · 2026Article
- MOGAN for LUAD Subtype Classification by Integrating Three Omics Data Types.Cancer innovation · 2025Article
- First Indonesian Nasopharyngeal Cancer Whole Epigenome Sequencing Identify Tumour Suppressor CpG Methylation.Biologics : targets & therapy · 2025Article
- MiR-4664-3p as a potential diagnostic, prognostic, and immunotherapeutic biomarker in NSCLC: modulation of tumor progression through CD8 + T cell regulation.Frontiers in oncology · 2025Article
- Transcriptome-wide N6-methyladenosinem modifications analysis of chicken cecum in responding toFrontiers in immunology · 2025Article
- Identification of biomarkers related toHeliyon · 2024Article
- A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights.Nature communications · 2024Article
- Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer.Scientific reports · 2024Article
- DNA Methylation Analysis Reveals Potential Mechanism in Takifugu rubripes Against Cryptocaryon irritans Infection.Marine biotechnology (New York, N.Y.) · 2024Article
- Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect ofOncology research · 2024Article
- DriverMP enables improved identification of cancer driver genes.GigaScience · 2022Article
- PRKCB is relevant to prognosis of lung adenocarcinoma through methylation and immune infiltration.Thoracic cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is one of the tumor-related diseases with high morbidity worldwide. Epigenetic modifications such as DNA methylation changes may involve in tumorigenesis. This study aimed to explore new biomarkers that have prognostic significance of LUAD.
methodsFirst, we downloaded the gene expression and methylation data set from Gene Expression Omnibus. R software was then used to identify abnormally methylated differentially expressed genes (MDEGs). Next, R package Cluster Profiler was used to analyze the enrichment and pathway of the MDEGs. Analysis using STRING revealed the protein-protein interaction network. The result was then visualized by Cytoscape and obtained 10 hub genes. Afterward, they were further verified by The Cancer Genome Atlas to select candidate genes. Moreover, quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to verify the expression and prognostic value of candidate genes in LUAD patients.
resultsThe results showed that the expressions of ADCY5 and PRKCB are indeed related to LUAD. The clinical relevance to PRKCB was confirmed by its clinical correlation analysis. Gene set enrichment analysis (GSEA) and tumor immune estimation resource (TIMER) tumor immune correlations showed that PRKCB is involved in the cancer-related Kyoto Encyclopedia of Genes and Genomes pathway and is involved in immune infiltration. It was also verified by qRT-PCR and immunohistochemistry that PRKCB was lowly expressed in LUAD patients and correlated with prognosis.
conclusionsPRKCB is relevant to prognosis of LUAD through methylation and immune infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.